Last updated on December 2018

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies


Brief description of study

This is an open-label, multicenter, dose-escalation Phase 1/1b study in patients with acute myelogenous leukemia (AML)/MDS or non-Hodgkin Lymphoma (NHL), intended to investigate safety, pharmacokinetics, and the pharmacodynamic effects of FT-1101 administered via one or more intermittent dosing schedules alone and in combination with azacitidine. Once the MTD has been established for a treatment cohort, up to 20 additional patients may be enrolled in up to 4 expansion cohorts each of select populations of patients with either AML/MDS or NHL at the recommended dose for future studies to confirm safety.

Clinical Study Identifier: NCT02543879

Contact Investigators or Research Sites near you

Start Over

Clinical Trials Office

Cedars Sinai
Los Angeles, CA United States
  Connect »

Manish Patel, MD

Florida Cancer Specialists
Sarasota, FL United States
  Connect »

Lisa Nardelli

Moffitt Cancer Center
Tampa, FL United States
  Connect »

Deborah Lewis, RN, BSN, CCRP

Levine Cancer Institute
Charlotte, NC United States
  Connect »

Renee Thompson

Sarah Cannon Research Institute
Nashville, TN United States
  Connect »

Ricardo Delumpa

MD Anderson Cancer Center
Houston, TX United States
  Connect »

Shira Dinner, MD

Northwestern University
Chicago, IL United States
  Connect »

Maria Baer, MD

University of Maryland, Greenebaum Comprehensive Cancer Center
Baltimore, MD United States
  Connect »